Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy.

Microbial pathogenesis - 1 Apr 2017

Karbalaie Niya Mohammad Hadi, Salman-Tabar Samira, Bokharaei-Salim Farah, Behmanesh Mehrdad, Keyvani Hossein

Abstract excerpt

BACKGROUND: Viral hepatitis C is an important global health problem that affects about 2.2% of humans. Strategies on the control of this hepatotropic virus focused on chemotherapy and surveillance of emerging HCV drug resistant mutants, respectively. HCV genotype 1 response to therapy is one of major interests. The aim of this research was to study the prevalence of resistant associated variants (RAVs) in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Point Mutation

Share to Sofosbuvir

Share to Viral Load

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 28161357
DOI: 10.1016/j.micpath.2017.01.060

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy.PMID 28161357Read ↗

Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants.Semantic proximity Read ↗

Hepatitis C virus resistance to the new direct-acting antiviralsSemantic proximity Read ↗

Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients.Semantic proximity Read ↗

[Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].Semantic proximity Read ↗

Frequency distribution of HCV resistance-associated variants in infected patients treated with direct-acting antivirals.Semantic proximity Read ↗

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus InfectionsSemantic proximity Read ↗

Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data.Semantic proximity Read ↗

Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals.Semantic proximity Read ↗

Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018.Semantic proximity Read ↗

Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis.Semantic proximity Read ↗

Characterization of Primary Direct Acting Antiviral Drugs (DAA) Resistance Mutations in NS5A/NS5B Regions of Hepatitis C Virus with Genotype 1a and 1b from Patients with Chronic HepatitisSemantic proximity Read ↗

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.